key: cord-0853750-2g3scvun
authors: Raoult, Didier
title: How useful is serology for COVID-19?
date: 2020-10-28
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.10.058
sha: 956708f4fdf27c0178799aa5b44fb5475a3dfad1
doc_id: 853750
cord_uid: 2g3scvun

• SARS-CoV-2; • Seroprevalence; • Performing serology retrospectively; • How to evaluate the extand of the epidemics.

A paper in this journal, reports on the different sero-epidemiological studies carried out around the world for SARS-CoV-2 1 . This study helps to put into perspective the potential interest of serology in SARS-CoV-2 infection. The first question was, according to serological techniques, is it possible to identify positive serologies in patients sampled in 2019, before the epidemic? The answer is yes 8 . Depending on the different serological techniques used, cross-reactions may be observed, particularly in children, which could explain why SARS-CoV-2is to date the only respiratory viral disease that does not affect children 2;3 . Indeed, in most cases, children are the most affected by respiratory viral infections, this situation is reversed for SARS-CoV-2 for reasons that are not clear at this time. The second major interest that these serological studies could have, would be to confirm a posteriori that patients who were included in studies based on purely clinical criteria were actually infected with SARS-CoV-2. Indeed, several studies, including the Recovery study in England and that of Skipper et al. 4;5 , have included in their evaluation patients who had not been tested, or tested negative, at the time of inclusion. Performing serology retrospectively, as in one recent study for example 6 , ensures that the patients included were indeed affected with SARS-CoV-2. A recent study conducted in France, shows that the predictive value of the clinical diagnosis of SARS-CoV-2 in patients who were subsequently serologically tested for SARS-CoV-2 is less than 50% 7 . This means that studies in which there was no diagnostic test to confirm the diagnosis included at least 50% of people who were not infected with SARS-CoV-2. This also depends on the sensitivity of the serological test. This makes series without a diagnostic test hard to interpret. Seroprevalence studies help to evaluate the extension of epidemics. Incidences based on samples tested by PCR from one area to another have not provided a complete epidemiological picture of the spread and lethality of the disease. In

Marseilles, we have systematically tested all symptomatic and non-symptomatic people since

February 2020 8 and have tested 10% of the whole population. We were therefore able to J o u r n a l P r e -p r o o f evaluate the percentage of positive people in the initial epidemic (incidence), at 8%. We had also samples of peoples from three other regions in France: the Ile de France (which includes Paris), the Grand Est, and the New Aquitaine regions. The incidence rates among patients tested in these regions by PCR (unpublished data) surprisingly give a result exactly superimposable to that of seroprevalence in the whole population of these areas, with 8% for Marseille area (Etablissement Français du Sang, France, unpublished data), 10% for Ile de France, 9% for Grand Est and 3% for Aquitaine 3 . The extent of population seroprevalence in a region or country will provide a sense of the importance of social control measures such as lockdown, the use of masks, or generalized testing. Moreover, it may allow clarifying the lethality in our area independently of the qPCR testing capacity during the outbreak. In the work carried out in this field, particularly in Italy 9 and Spain 10 , it has been shown that persons confined in house, when not tested for putative contagiosity, have more often been positive than working unconfined persons. This is counter-intuitive, as the consequence that SARS-CoV-2 carriers have not been detected. This raises the question of the value of the lockdown of families when asymptomatic carriers are not detected. Seroprevalence is also a very good evaluation of the prevention measures of the health care staff. In general, the measurement of seroprevalence in Spain 10 and Italy 9 showed much higher prevalence of the health care personnel, indicating a weakness in prevention measures as well as their high risk.

In Marseilles, the percentage of positive test results among health care staff in direct contact remained very low in may 2020, at 3.5% 11 , due to the importance of the protective measures deployed. As a matter of fact, we had to import protective artefacts directly from China, as no stock was available in France. All in all, this work opens the door to a more general reflection on the conduct of epidemiological studies in order to refine the consequences of social or protective measures in the spread of the virus in a given site. 

Po Ren Hsueh. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review

Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adults

Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads

Randomised Evaluation of COVID-19 Therapy

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial

COVID-19 Outpatients -Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France